Synthaverse S.A. (SVE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Synthaverse S.A. (SVE) has a cash flow conversion efficiency ratio of 0.072x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł8.68 Million ≈ $2.39 Million USD) by net assets (zł120.93 Million ≈ $33.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Synthaverse S.A. - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Synthaverse S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SVE liabilities breakdown for a breakdown of total debt and financial obligations.
Synthaverse S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synthaverse S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Schwager
SN:SCHWAGER
|
0.113x |
|
CBAK ENERGY TECH. NEW
F:B6JA
|
0.272x |
|
Enex Co.Ltd
KO:011090
|
-0.124x |
|
Millie Seojae.
KQ:418470
|
0.040x |
|
Genetec Technology Bhd
KLSE:0104
|
-0.110x |
|
Chosun Welding
KO:120030
|
0.009x |
|
AML3D Ltd
AU:AL3
|
-0.076x |
|
Professional Computer Technology Ltd
TWO:6270
|
0.039x |
Annual Cash Flow Conversion Efficiency for Synthaverse S.A. (2010–2024)
The table below shows the annual cash flow conversion efficiency of Synthaverse S.A. from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Synthaverse S.A. (SVE) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł121.47 Million ≈ $33.43 Million |
zł13.73 Million ≈ $3.78 Million |
0.113x | +338.13% |
| 2023-12-31 | zł112.64 Million ≈ $31.00 Million |
zł-5.34 Million ≈ $-1.47 Million |
-0.047x | -269.91% |
| 2022-12-31 | zł105.56 Million ≈ $29.05 Million |
zł2.95 Million ≈ $811.33K |
0.028x | +163.46% |
| 2021-12-31 | zł74.55 Million ≈ $20.52 Million |
zł-3.28 Million ≈ $-902.98K |
-0.044x | -578.66% |
| 2020-12-31 | zł37.31 Million ≈ $10.27 Million |
zł343.00K ≈ $94.40K |
0.009x | -96.30% |
| 2019-12-31 | zł32.87 Million ≈ $9.05 Million |
zł8.16 Million ≈ $2.25 Million |
0.248x | +1317.34% |
| 2018-12-31 | zł30.40 Million ≈ $8.37 Million |
zł-620.00K ≈ $-170.63K |
-0.020x | -127.07% |
| 2017-12-31 | zł57.81 Million ≈ $15.91 Million |
zł4.36 Million ≈ $1.20 Million |
0.075x | -99.46% |
| 2016-12-31 | zł1.13 Million ≈ $310.17K |
zł15.77 Million ≈ $4.34 Million |
13.993x | +9585.14% |
| 2015-12-31 | zł20.00 Million ≈ $5.51 Million |
zł-2.95 Million ≈ $-812.18K |
-0.148x | -566.59% |
| 2014-12-31 | zł57.25 Million ≈ $15.76 Million |
zł-1.27 Million ≈ $-348.68K |
-0.022x | +81.02% |
| 2013-12-31 | zł58.49 Million ≈ $16.10 Million |
zł-6.82 Million ≈ $-1.88 Million |
-0.117x | +37.91% |
| 2012-12-31 | zł44.75 Million ≈ $12.32 Million |
zł-8.40 Million ≈ $-2.31 Million |
-0.188x | +42.69% |
| 2011-12-31 | zł50.06 Million ≈ $13.78 Million |
zł-16.41 Million ≈ $-4.51 Million |
-0.328x | -268.73% |
| 2010-12-31 | zł14.06 Million ≈ $3.87 Million |
zł-1.25 Million ≈ $-343.86K |
-0.089x | -- |
About Synthaverse S.A.
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more